Literature DB >> 12374357

Self-reported herpes labialis in a Swedish population.

Gun-Britt Löwhagen1, Ellen Bonde, Bo Eriksson, Per Nordin, Petra Tunbäck, Ingela Krantz.   

Abstract

In a cross-sectional study, the occurrence of a self-reported history of labial herpes was evaluated. The study population comprised a stratified random sample of 5,000 individuals, aged 0-60 y, from south-west Sweden. A questionnaire, together with written and photographic descriptions of labial herpes lesions, was sent to the participants. Of 5,000 questionnaires sent out, 3597 (72%) were returned. In answer to the question "Have you ever had herpes?" the point estimate was 26.6% (95% confidence interval [CI] 25.1%-28.1%) and for the question "Have you had herpes in the last 2 y?" it was 19.4 (95% CI 18.0-20.8). The proportion of individuals who had had herpes was higher for the older age groups. About 5% of children aged < or = 5 y had experienced labial herpes. Herpes was more frequently reported by females than males: odds ratio 1.29 (95% CI 1.10-1.51). Compared to previous studies in Sweden, our data do not indicate that the occurrence of labial herpes lesions has decreased.

Entities:  

Mesh:

Year:  2002        PMID: 12374357     DOI: 10.1080/00365540210147732

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  2 in total

Review 1.  Laser treatment of recurrent herpes labialis: a literature review.

Authors:  Carlos de Paula Eduardo; Ana Cecilia Corrêa Aranha; Alyne Simões; Marina Stella Bello-Silva; Karen Muller Ramalho; Marcella Esteves-Oliveira; Patrícia Moreira de Freitas; Juliana Marotti; Jan Tunér
Journal:  Lasers Med Sci       Date:  2013-04-13       Impact factor: 3.161

2.  Herpes simplex virus type I-infected disorders alter the balance between Treg and Th17 cells in recurrent herpes labialis patients.

Authors:  Xian-Xian Mei; Shan-Shan Lei; Li Xu; Shan Wu; Huan-Peng Gu; Yu Du; Ting Zhao; Guan-Qun Xie; Yong-Sheng Fan; Xiao-Ping Pan; Jie Bao
Journal:  Int J Immunopathol Pharmacol       Date:  2020 Jan-Dec       Impact factor: 3.219

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.